Latent autoimmune hepatitis in non-B non-C chronic liver diseases.

Treatment of chronic hepatitis B, delta related liver disease and non-A non-B hepatitis.

[Non-invasive evaluation of liver fibrosis in chronic hepatitis C].

Chronic hepatitis C (CHC) is a major public health concern, with around 180 million individuals affected worldwide. Liver fibrosis and its end-point cirrhosis are the main causes of morbidity and mortality in patients with CHC. Liver biopsy (LB) has traditionally been considered the "gold standard" for pre-treatment evaluation of liver fibrossis in patients with CHC. However, LB is an invasive ...

Non Alcoholic Fatty Liver Diseases in Chronic Hepatitis C: Impact on End Treatment Virologic Response

Background: Both nonalcoholic fatty liver disease (NAFLD) and chronic hepatitis C (CHC) are frequent causes of chronic liver disease. Questions remain regarding the etiology of steatosis and steatohepatitis in hepatitis C, and its impact on disease progression and treatment outcomes. Objectives: To estimate the association of NAFLD with CHC and to evaluate the effect of steatosis and non alcoho...

Comparison of non-invasive assessment to diagnose liver fibrosis in chronic hepatitis B and C patients.

OBJECTIVE Chronic viral hepatitis B and C cause liver fibrosis, leading to cirrhosis. Fibrosis assessment is essential to establish prognosis and treatment indication. We compared seven non-invasive tests, separately and in combination, in chronic hepatitis patients to detect early stages of fibrosis according to the Metavir score in liver biopsy. MATERIAL AND METHODS Galactose and methacetin...

Chronic non-A, non-B hepatitis: role of hepatitis C virus.

Thirty three consecutive children with chronic non-A, non-B hepatitis (NANBH) were studied during a four year period to evaluate clinical and histological features and the role of hepatitis C virus (HCV). All patients were asymptomatic. Thirteen (39%) of them were anti-HCV positive. A history of parenteral exposure was significantly more frequent among anti-HCV positive (69%) than anti-HCV nega...